Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study
| Title: | Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study |
|---|---|
| Authors: | Paz-Ares, L.; Chen, Y.; Reinmuth, N.; Hotta, K.; Trukhin, D.; Statsenko, G.; Goldman, J. W. |
| Publisher Information: | Elsevier |
| Publication Year: | 2021 |
| Description: | [No Abstract Available] ; AstraZenecaAstraZeneca ; AstraZeneca. |
| Document Type: | conference object |
| File Description: | application/pdf |
| Language: | English |
| Relation: | Annals Of Oncology; Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı; https://doi.org/10.1016/j.annonc.2021.08.2142; https://hdl.handle.net/20.500.12831/6596; 32; S1338; Q1; WOS:000700527704021 |
| DOI: | 10.1016/j.annonc.2021.08.2142 |
| Availability: | https://doi.org/10.1016/j.annonc.2021.08.2142; https://hdl.handle.net/20.500.12831/6596 |
| Rights: | info:eu-repo/semantics/openAccess |
| Accession Number: | edsbas.E2537810 |
| Database: | BASE |